LYRA vs. INO, MODD, NXL, MBOT, BLAC, OM, CLGN, BDMD, MDAI, and NMTC
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Inovio Pharmaceuticals (INO), Modular Medical (MODD), Nexalin Technology (NXL), Microbot Medical (MBOT), Bellevue Life Sciences Acquisition (BLAC), Outset Medical (OM), CollPlant Biotechnologies (CLGN), Baird Medical Investment (BDMD), Spectral AI (MDAI), and NeuroOne Medical Technologies (NMTC). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs.
Inovio Pharmaceuticals (NASDAQ:INO) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Lyra Therapeutics. MarketBeat recorded 3 mentions for Inovio Pharmaceuticals and 0 mentions for Lyra Therapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.36 beat Lyra Therapeutics' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.
Inovio Pharmaceuticals received 696 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 71.15% of users gave Inovio Pharmaceuticals an outperform vote while only 60.00% of users gave Lyra Therapeutics an outperform vote.
Inovio Pharmaceuticals has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,635.76%. Inovio Pharmaceuticals' return on equity of -118.17% beat Lyra Therapeutics' return on equity.
26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 2.5% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Lyra Therapeutics has higher revenue and earnings than Inovio Pharmaceuticals.
Inovio Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500.
Inovio Pharmaceuticals presently has a consensus price target of $12.40, suggesting a potential upside of 484.91%. Lyra Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 2,150.00%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Inovio Pharmaceuticals.
Summary
Inovio Pharmaceuticals beats Lyra Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 2/19/2025 by MarketBeat.com Staff